H.C. Wainwright Signal Clinical Data to Drive CorMedix Inc. (CRMD) Future Over Commercial Performance

We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. CorMedix Inc. tops our list for being one of the high growth stocks.

TheFly reported on January 23 that H.C. Wainwright lowered the price target on CRMD to $13 from $18 while keeping a Buy rating. The adjustment reflects updated guidance for 2026–2027 related to DefenCath. The firm noted that CRMD has now entered a phase where clinical results will play a larger role than commercial performance in shaping the company’s future.

H.C. Wainwright Signal Clinical Data to Drive CorMedix Inc. (CRMD) Future Over Commercial Performance

Similarly, on January 21, RBC Capital lowered the price target on CorMedix Inc. (NASDAQ:CRMD) to $13 from $22 while maintaining an Outperform rating. The firm updated its models for several biotech companies following discussions with management.

CorMedix Inc. (NASDAQ:CRMD) is a biopharmaceutical company developing and commercializing therapeutic products to prevent and treat serious diseases. Its lead product, DefenCath, is an FDA‑approved catheter lock solution that reduces bloodstream infections in hemodialysis patients.

While we acknowledge the risk and potential of CRMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRMD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.